Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
Eli Lilly will participate in the UBS Global Healthcare Virtual Conference on May 26, 2021, at 10:00 a.m. ET. Anat Ashkenazi, CFO, will engage in a virtual fireside chat during the event. A live audio webcast will be hosted on Lilly’s Investor website, with a replay available for 90 days. Founded over a century ago, Eli Lilly is dedicated to discovering and delivering innovative medicines globally. To learn more about the company, visit www.lilly.com.
Eli Lilly and Company (NYSE: LLY) has entered a global research collaboration with MiNA Therapeutics to explore novel drug candidates using MiNA's small activating RNA (saRNA) technology. MiNA will investigate up to five targets identified by Lilly, which will handle preclinical and clinical development, retaining exclusive commercialization rights. MiNA will receive a $25 million upfront payment and is eligible for additional milestones totaling $245 million per target. The collaboration is expected to enhance Lilly's RNA therapeutics portfolio without impacting its 2021 non-GAAP earnings per share guidance.
Eli Lilly and Company (NYSE: LLY) announced strategic partnerships with DexCom, Glooko, myDiabby Healthcare, and Roche to enhance diabetes management through connected technology. These collaborations aim to integrate their diabetes management platforms with Lilly's Tempo Pen and Tempo Smart Button, expected to improve real-time data tracking for insulin users. Lilly seeks CE marking for the Tempo Smart Button later in 2021 and plans to launch these products internationally. The initiatives target the growing diabetes community, addressing management challenges and improving treatment outcomes.
Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Securities 2021 Health Care Conference on May 11, 2021. Senior VP Michael Mason, who leads Lilly Diabetes, will engage in a virtual fireside chat at 9:30 a.m. Eastern Time. A live audio webcast will be accessible on Lilly's Investor website, with a replay available for 90 days.
Lilly continues its mission to create high-quality medicines, supporting global health through discovery and community engagement. For more information, visit www.lilly.com.
Eli Lilly is donating COVID-19 therapies, including baricitinib, bamlanivimab, and etesevimab, to Direct Relief. This initiative aims to provide treatments at no cost to low- and lower-middle-income countries severely affected by the pandemic. The donation will assist hospitalized patients needing supplemental oxygen and those at high risk of severe illness. Lilly's effort aligns with its philanthropic goal to improve healthcare access for 30 million people each year by 2030. The program will be continuously assessed based on pandemic conditions in target countries.
Eli Lilly and Company (NYSE: LLY) announced assistance initiatives for COVID-19 patients in India. The company is donating 400,000 tablets of baricitinib to the Indian government and is collaborating with local firms for royalty-free licenses to expedite production. Baricitinib has received emergency use authorization for hospitalized patients needing oxygen support. CEO David A. Ricks emphasized the urgency of improving access to this treatment amidst India’s COVID-19 crisis.
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a $0.85 per share dividend for Q2 2021, payable on June 10, 2021. Shareholders must be on record by May 14, 2021. Additionally, the board authorized a $5 billion share repurchase program, complementing the remaining $1 billion from a prior authorization initiated in June 2018. Purchases will occur at management's discretion with no set timeline.
Eli Lilly has pledged $5 million over five years to support Direct Relief's Fund for Health Equity, which aims to enhance healthcare access in underserved communities. This commitment is part of Lilly's broader Racial Justice Initiative, addressing systemic health inequities affecting minority groups. Direct Relief focuses on strengthening health organizations through grants that improve leadership, preventive strategies, chronic disease management, and access to innovative technologies.
Eli Lilly reported Q1 2021 financial results with revenue of $6.806 billion, a 16% increase from Q1 2020. Net income decreased 7% to $1.355 billion, with a reported EPS of $1.49. Non-GAAP net income rose 16% to $1.702 billion, with an EPS of $1.87. Key growth products contributed 46% of total revenue, driven by strong sales in diabetes and cancer treatment. Lilly's COVID-19 antibodies generated $810.1 million in revenue. Despite increased R&D expenses by 21%, Lilly gained significant advancements in clinical trials for several promising therapies.
FAQ
What is the current stock price of Lilly Eli & Co (LLY)?
What is the market cap of Lilly Eli & Co (LLY)?
